FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
PHILADELPHIA, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN), today announced the signing of a license with Stanford University providing exclusive rights to certain breakthrough gene therapy technologies developed in the labs of Professor Mark A. Kay, M.D., Ph.D., Dennis Farrey Family Professor in Pediatrics, Professor of Genetics, at Stanford University School of Medicine. Under the license, Medgenics gains the exclusive right for the autologous ex vivo use of Stanford’s GeneRide novel promoter-less gene therapy technology in combination with Medgenics’ proprietary TARGTTM technology. Medgenics also receives the exclusive right to use this technology for the delivery of hematopoietic stem cells for sickle cell anemia and beta thalassemia.
“We are excited to gain access to the GeneRide technology, combining the benefits of AAV vector gene transfer with the potential for permanent delivery of therapeutic proteins and peptides,” said Garry Neil, MD, Chief Scientific Officer of Medgenics. “Most importantly, this system is designed to allow efficient and predictable integration into precisely defined sites, using naturally occurring promoters.”
“By avoiding off-target integration the GeneRide system could provide a comparably safer approach than other competing gene therapies,” said Mike Cola, Medgenics CEO. “The additional capabilities afforded by the Stanford technology puts us in a position to be a leader in ex vivo gene therapy.”
About Medgenics, Inc.
Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. Medgenics is the developer of TARGTTM (Transduced Autologous Restorative Gene Therapy), a proprietary platform for the sustained production and delivery of therapeutic proteins, monoclonal antibodies and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases. For more information, visit the Company's website at www.medgenics.com.
Contacts: Medgenics, Inc.: John Leaman [email protected] Brian Piper [email protected] Stern Investor Relations: Beth DelGiacco 212-362-1200 [email protected]
